Invention Grant
- Patent Title: SARS-CoV-2 epitope-targeted peptide immunostimulants
-
Application No.: US17336276Application Date: 2021-06-01
-
Publication No.: US12209142B2Publication Date: 2025-01-28
- Inventor: James R. Heath , Matthew Idso , Alexander J. Winton , Matthew B. Coppock , Sanchao Liu
- Applicant: Institute for Systems Biology , The United States of America as Represented by The Secretary of the Army
- Applicant Address: US WA Seattle; US DC Washington
- Assignee: Institute for Systems Biology,The United States of America as Represented by The Secretary of the Army
- Current Assignee: Institute for Systems Biology,The United States of America as Represented by The Secretary of the Army
- Current Assignee Address: US WA Seattle; US DC Washington
- Agency: Fenwick & West LLP
- Agent Carl A. Morales; Cara A. Mosley
- Main IPC: A61K38/07
- IPC: A61K38/07 ; A61K38/08 ; A61K47/55 ; A61K47/64 ; C07K5/103 ; C07K7/06 ; C07K7/08 ; A61K38/00

Abstract:
Disclosed are compounds, compositions, and methods relating to epitope-targeted immunostimulants (EPIs), which comprise a synthetic peptide ligand and an antibody-recruiting moiety. The peptide ligand binds an epitope on a target and the antibody-recruiting moiety recruits antibodies to the target when the EPI is bound to the epitope on the target. Also disclosed are compositions comprising any of the disclosed EPIs. Also disclosed are methods of stimulating an immune reaction to a microorganism or other pathogen in a subject where an EPI is administered to the subject. Also disclosed are methods of identifying the peptide ligand by using multi-omic analysis.
Public/Granted literature
- US20210380640A1 SARS-CoV-2 EPITOPE-TARGETED PEPTIDE IMMUNOSTIMULANTS Public/Granted day:2021-12-09
Information query
IPC分类: